Exodus Point Capital Management, LP Macrogenics Inc Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$4.48 - $6.19 $250,042 - $345,482	55,813 Added 503.68%	66,894 $312,000
Q2 2023 Aug 10, 2023	BUY	$4.62 - $7.54 $51,194 - $83,550	11,081 New	11,081 $59,000
Q3 2022 Nov 10, 2022	SELL	$3.01 - $5.22 $101,704 - $176,378	-33,789 Reduced 53.91%	28,892 $100,000
Q2 2022 Aug 19, 2022	BUY	$2.25 - $9.99 $141,032 - $626,183	62,681 New	62,681 $185,000
Q1 2022 May 13, 2022	SELL	$8.12 - $16.9 $529,529 - $1.1 Million	-65,213 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$15.91 - $21.88 $209,439 - $288,028	-13,164 Reduced 16.8%	65,213 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $1.55 Million - $2.25 Million	78,377 New	78,377 $1.64 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $676,851 - $866,282	-27,414 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $142,552 - $798,295	27,414 New	27,414 $765,000
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $69,990 - $198,034	-16,353 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $130,006 - $200,651	16,353 New	16,353 $178,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.